



# HHS Public Access

Author manuscript

*Nat Immunol.* Author manuscript; available in PMC 2010 April 01.

Published in final edited form as:

*Nat Immunol.* 2009 October ; 10(10): 1125–1132. doi:10.1038/ni.1783.

## Thymic self-reactivity selects natural interleukin 17-producing T cells that can regulate peripheral inflammation

Benjamin R. Marks<sup>1</sup>, Heba N. Nowyhed<sup>1</sup>, Jin-Young Choi<sup>2</sup>, Amanda C. Poholek<sup>3</sup>, Jared M. Odegard<sup>1</sup>, Richard A. Flavell<sup>1,4</sup>, and Joe Craft<sup>1,2</sup>

<sup>1</sup>Department of Immunobiology, Yale School of Medicine, New Haven, CT 06520, USA

<sup>2</sup>Section of Rheumatology, Department of Internal Medicine, Yale School of Medicine, New Haven, CT 06520, USA

<sup>3</sup>Department of Cell Biology, Yale School of Medicine, New Haven, CT 06520, USA

<sup>4</sup>Howard Hughes Medical Institute, Yale School of Medicine, New Haven, CT 06520, USA

### Abstract

Interleukin 17 (IL-17)-producing CD4<sup>+</sup> T (T<sub>H</sub>-17) cells share a developmental relationship with FoxP3<sup>+</sup> regulatory T (T<sub>reg</sub>) cells. Here we show that a T<sub>H</sub>-17 population differentiates within the thymus in a manner influenced by self-antigen recognition, and by the cytokines IL-6 and transforming growth factor (TGF)- $\beta$ . Like previously described T<sub>H</sub>-17 cells, T<sub>H</sub>-17 cells that develop in the thymus expressed the orphan nuclear receptor ROR $\gamma$ t and the IL-23 receptor. These cells also expressed  $\alpha$ 4 $\beta$ 1 integrins and the chemokine receptor CCR6, and were recruited to the lung, gut, and liver. In the liver these cells secreted IL-22 in response to self-antigen and mediated host protection during inflammation. Thus, T<sub>H</sub>-17 cells, like T<sub>reg</sub> cells, can be selected by self-antigens in the thymus.

### Introduction

CD4<sup>+</sup> T helper (T<sub>H</sub>) cells play a major role in orchestrating immune responses. For nearly 20 years, the T<sub>H</sub> differentiation paradigm consisted of two mutually exclusive pathways, T<sub>H</sub>1 and T<sub>H</sub>2, which were defined by expression of distinct transcription factors and cytokines<sup>1</sup>. T<sub>H</sub>1 cells express the transcription factor T-bet and produce interferon (IFN)- $\gamma$ , which directs cell mediated immunity by promoting clearance of intracellular pathogens<sup>2</sup>, and is responsible for delayed type hypersensitivity reactions. T<sub>H</sub>2 cells express the transcription factor GATA-3 and produce IL-4, IL-5 and IL-13, which facilitate host protection against extracellular parasites and are major effectors in atopic disease<sup>2</sup>. More recently, an IL-17 producing subset (T<sub>H</sub>-17) was recognized as a third CD4<sup>+</sup> T cell effector

Users may view, print, copy, download and text and data- mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use: [http://www.nature.com/authors/editorial\\_policies/license.html#terms](http://www.nature.com/authors/editorial_policies/license.html#terms)

Correspondence should be sent to J.C. ([joseph.craft@yale.edu](mailto:joseph.craft@yale.edu)).

**AUTHOR CONTRIBUTIONS** B.R.M. and J.C. designed experiments; B.R.M., H.N.N., J-Y. C., A.C.P., and J.M.O. performed the experiments; B.R.M., H.N.N., J-Y.C., R.A.F. and J.C. analyzed the data; B.R.M. and J.C. wrote the paper.

The authors declare that they have no financial conflicts of interest.

lineage that plays a critical role during the early innate phase of the immune response<sup>3,4</sup>. T<sub>H</sub>-17 cells promote the clearance of extracellular pathogens by recruiting neutrophils, and by inducing production of anti-microbial proteins and inflammatory factors from resident cells.

T<sub>H</sub>-17 cells express the transcription factors ROR $\gamma$ t5 (<http://www.signaling-gateway.org/molecule/query?afcsid=A002302>) and ROR $\alpha$ 6, produce IL-22 and IL-17F8 in addition to IL-17 (IL-17A), and express the IL-23 receptor (IL-23R)<sup>9</sup>. Early work established IL-23 as a survival factor for T<sub>H</sub>-17 cells<sup>4</sup>, and showed that *in vitro* differentiation of T<sub>H</sub>-17 cells unexpectedly proceeded via a developmental pathway partially shared with the anti-inflammatory FoxP3<sup>+</sup> regulatory T cell (T<sub>reg</sub>) population. Activating naïve T cells *in vitro* in the presence of transforming growth factor (TGF)- $\beta$  (<http://www.signaling-gateway.org/molecule/query?afcsid=A002271>) alone promotes development of T<sub>reg</sub> cells, and the addition of IL-6 diverts differentiation to the T<sub>H</sub>-17 lineage<sup>10–12</sup>. Further supporting a relationship between these subsets, IL-2--a cytokine necessary for T<sub>reg</sub> survival<sup>13</sup>--constrains T<sub>H</sub>-17 cell differentiation; even in the presence of TGF $\beta$  and IL-6, IL-2 suppresses T<sub>H</sub>-17 development and expands T<sub>reg</sub> cell populations<sup>14</sup>. Inflammatory conditions, mimicked by the addition of IL-1, rescues the inhibitory effect of IL-2 and restores T<sub>H</sub>-17 differentiation<sup>15</sup>. In addition, T<sub>reg</sub> cells can convert directly to T<sub>H</sub>-17 producing cells under particular inflammatory conditions<sup>16</sup>, and retinoic acid produced by dendritic cells (DC) within the gut abrogates inflammation by suppressing T<sub>H</sub>-17 and enhancing T<sub>reg</sub> cell differentiation<sup>17</sup>. More recent work provided definitive data defining a common developmental pathway between these two subsets in that TGF $\beta$  operates in a concentration-dependent manner allowing the induction of both FoxP3 and ROR $\gamma$ t; differentiation to the T<sub>H</sub>-17 pathway, for example, is determined by factors such as IL-23 and IL-21, which prevent the direct binding of FoxP3 to ROR $\gamma$ t<sup>18</sup>. FoxP3 and ROR $\gamma$ t can both bind to Runx1, and Runx1 promotes ROR $\gamma$ t-mediated T<sub>H</sub>-17 cell induction while facilitating FoxP3 suppression of ROR $\gamma$ t<sup>19</sup>. Further support for a common development of these two lineages comes from the observation that thymocytes which would in wild-type mice become T<sub>reg</sub> cells, instead express ROR $\gamma$ t and produce IL-17 in mice unable to express FoxP3 due to genetic insertion of GFP in the *Foxp3* locus<sup>20</sup>. Thus, in the absence of FoxP3, natural mechanisms selecting the T<sub>reg</sub> lineage default to the T<sub>H</sub>-17 lineage.

Self-antigen presentation, important for central tolerance via removal of immature T cells expressing potentially autoreactive T cell receptors (TCR), is also necessary for selection of self-reactive subsets of T cells. These most notably include natural T<sub>reg</sub><sup>21,22</sup>, CD1d-restricted natural killer T cells<sup>23</sup>, CD8 $\alpha$  intra-epithelial lymphocytes<sup>24</sup> and  $\gamma$  $\delta$  T cells<sup>25</sup>. Thus, in addition to the production of naïve T cells that migrate to secondary lymphoid organs where they await activation and differentiation, the thymus produces distinct, often smaller, populations of T cells that leave the thymus as differentiated effector populations with the capacity to fine tune the immune response. Here we sought to identify other effector cell subsets that are selected based upon self-reactivity. We specifically focused upon the T<sub>H</sub>-17 subset given its developmental relationship with T<sub>reg</sub> cells. We demonstrate that the lineage relationship between T<sub>reg</sub> and T<sub>H</sub>-17 cells can be extended to include development in the thymus in response to self-antigen.

## RESULTS

### Self-reactivity enriches for T<sub>H</sub>-17 cells

To explore the influence of self-reactivity on the differentiation of distinct T cell subsets, we used a model of natural T<sub>reg</sub> cell enrichment in which mice express a TCR transgene as well as a transgene encoding a high affinity cognate antigen for this TCR<sup>21, 26</sup>. We bred B10.BR (H-2<sup>k</sup>) mice bearing the AND TCR transgene specific for a peptide of pigeon cytochrome *c* (PCC) with mice expressing PCC under control of an MHC class I promoter<sup>27</sup>. As expected, AND × PCC double transgenic (DTg) mice showed altered thymocyte development compared to control single transgenic (STg) mice expressing the AND transgene or the PCC transgene (Supplementary Fig. 1a). DTg mice exhibited reduction but not elimination of the peripheral CD4<sup>+</sup> T cell population (Fig. 1a). The majority of mature CD4<sup>+</sup> T cells in DTg mice expressed CD44 (Fig. 1b), indicating an activated or memory phenotype. Consistent with previous reports<sup>21, 26</sup>, DTg mice also showed enrichment of T<sub>reg</sub> cells as determined by FoxP3 expression (Fig. 1c). T<sub>reg</sub> cells made up only a fraction of the T cell population in DTg mice; we focused our studies on the remaining non-T<sub>reg</sub> CD4<sup>+</sup> T cells.

To determine the functional state of the peripheral CD4<sup>+</sup> T cells in the DTg mice, we assessed their proliferation and cytokine production after stimulation with antigen *in vitro*. In comparison to cells from STg AND mice, those from DTg animals required at least a log more antigen for activation (Fig. 1d), consistent with an antigen-tuning model<sup>28</sup>. However, having reached the threshold for stimulation, DTg T cells showed similar proliferation kinetics as cells from STg mice, as indicated by an identical proliferation index at higher antigen concentrations (Fig. 1d). In response to antigen, STg T cells secreted significantly more IL-2 than DTg T cells (Fig. 1e). However, DTg T cells produced more IL-17 and IFN- $\gamma$  than STg T cells (Fig. 1e). Intracellular cytokine staining and analysis of Foxp3 expression established the presence of three distinct and enriched T cell subsets in spleens of DTg mice: T<sub>reg</sub>, T<sub>H</sub>-17, and T<sub>H</sub>1 (Fig. 1f-h).

### Thymic selection of self-reactive T<sub>H</sub>-17 cells

The development of the T<sub>H</sub>-17 subset in DTg mice could occur intrathymically and/or peripherally, given the widespread tissue expression of the neoself-antigen, PCC. We used intracellular cytokine staining to show that the CD4 single positive (SP) thymocyte pool from DTg mice contained enriched populations of IL-17-producing as well as FoxP3<sup>+</sup> and IFN- $\gamma$ <sup>+</sup> cells (Fig. 2a, b); absolute numbers of T<sub>H</sub>-17 cells were also significantly increased in the thymus and LN of DTg compared to STg mice (Supplementary Fig. 1b). To confirm that these cells were of thymic origin and not re-circulating from peripheral tissues, we sorted HSA<sup>+</sup>CD4<sup>+</sup>CD8<sup>-</sup> SP thymocytes (Supplementary Fig. 2a, b) and cultured them with PCC. Like splenocytes, these thymocytes produced IL-17 intracellularly (Fig. 2c, d). As further confirmation of their immature status, DTg thymocytes producing IL-17 expressed a GFP cassette regulated by the recombinase activating gene-2 (*Rag2*) promoter<sup>29</sup>, like CD4<sup>+</sup>CD8<sup>+</sup> double positive (DP) thymocytes from the same mice; in comparison, IFN- $\gamma$ -producing cells found within the thymus expressed lower amounts of GFP (Fig. 2e). Next, we transferred CFSE-labeled CD4<sup>+</sup> T cells from the LN and spleens of DTg mice into PCC

STg recipients, to determine if they migrated to the thymus. Forty-eight hours post-transfer, we found that DTg T cells survived, albeit without proliferation (presumably due to TCR tuning)<sup>28</sup>, and populated the LN, lungs and liver but showed minimal movement to the thymus (Fig. 2f, Supplementary Fig. 2c). Finally, we analyzed AND × TA.TIM transgenic mice, in which PCC expression is restricted to thymic epithelial cells<sup>30</sup>. We observed enrichment in the percentage and number of IL-17-producing cells within the thymus and LN comparable to that found in DTg mice (Fig. 2g). Together, these results definitively demonstrated that IL-17 producing AND TCR Tg T cells develop in the thymus. In addition, given the thymus restricted self-antigen expression in TA.TIM mice, they indicate that following export from the thymus, these cells are found within secondary lymphoid organs even in the absence of self-antigen.

We next asked if DTg mice developed an inflammatory or autoimmune phenotype, given their enrichment of T<sub>H</sub>-17 cells in the setting of global expression of self-antigen. We therefore followed DTg mice up to 1 year of age, and found that their survival curves were identical to those of AND STg and wild-type animals (Supplementary Table 1). Moreover, concentrations of cytokines and chemokines (IL-1 $\alpha$ , IL-6, IL-10, IL-17, IFN- $\gamma$ , IL-12 (p40), tumor necrosis factor (TNF), MIP-1 $\alpha$  and RANTES), as well as IgM and autoantibodies (anti-DNA), were equivalent in sera of 12 wk-old DTg and wild-type mice; notably, both groups had reduced concentrations of cytokines and antibodies in comparison to age-matched autoimmune prone MRL/*Fas*<sup>lpr</sup> mice (Supplementary Fig. 3a, b). Serum concentrations of IL-17 and IFN- $\gamma$  were similar in DTg and wild-type mice, suggesting that the enriched T<sub>H</sub>-17 effector populations in DTg mice are present but appropriately suppressed. In addition, upon transfer to DTg recipients, naïve AND STg T cells allotype marked by CD90.1 failed to differentiate into IL-17 producing cells (Supplementary Fig. 3c). Thus spontaneous skewing to T<sub>H</sub>-17 did not occur in the peripheral environment of DTg mice, further supporting the role of the thymus in T<sub>H</sub>-17 cell differentiation.

To demonstrate that our observations were not limited to one DTg system or to the B10.BR mouse strain, we also bred mice bearing the OTII TCR transgene specific for a peptide of ovalbumin (OVA) in the context of H-2K<sup>b</sup> (C57BL/6) with those expressing OVA under the chicken beta actin promoter (Act-mOVA). In these OT-II × OVA DTg animals, percentages and absolute numbers of T<sub>H</sub>-17 cells were enriched within the thymus and LN to a degree similar to that found in AND × PCC DTg mice (Supplementary Fig. 4a–d). Finding a similar absolute number of T<sub>H</sub>-17 cells in two different double transgenic systems of different strains and presumed neoself-ag affinity indicates that other factors such as local or circulating cytokines may contribute to development of this subset, analogous to T<sub>reg</sub> cell dependence upon IL-213. Self-reactivity is presumably only one step in the pathway of thymic T<sub>H</sub>-17 cell differentiation.

Confirming the self-antigen specificity of the enriched T<sub>H</sub>-17 cell populations in DTg mice, stimulation of CD4<sup>+</sup> T cells from DTg mice with PCC peptide induced proliferation (Fig. 1d, Supplementary Fig. 5a), and IL-17 production (Fig. 1e, 2c). These experiments indicate that T<sub>H</sub>-17 thymocytes and splenocytes from DTg mice are neoself-ag specific, even in the setting of possible expression of endogenous TCR rearrangements in the Tg T cells. Nonetheless, we went on to demonstrate that T<sub>H</sub>-17 enrichment also occurred in the thymi

and spleens of *Rag1*<sup>-/-</sup> DTg mice (Supplementary Fig. 5b). These data, in aggregate, indicate that in DTg mice T<sub>H</sub>-17 cells may develop in the thymus upon selection by neoself-antigen, analogous to development of natural T<sub>reg</sub> cells<sup>21, 22</sup>.

### IL-6 and TGF- $\beta$ promote thymic T<sub>H</sub>-17 differentiation

IL-6 and TGF $\beta$  are critical for T<sub>H</sub>-17 differentiation *in vitro*<sup>10–12</sup> and *in vivo*<sup>31, 32</sup>. Thus, we asked if the same cytokines were necessary for development of thymic derived T<sub>H</sub>-17 cells in the absence of overt inflammation. We used DTg mice bred to animals either lacking IL-6 or expressing a dominant negative form of the TGF- $\beta$  receptor under control of the *Cd4* promoter<sup>33</sup>. In both cases, the T<sub>H</sub>-17 population was significantly reduced in the thymus and in peripheral lymphoid organs, while the T<sub>reg</sub> and T<sub>H</sub>1 populations were either unaffected or slightly increased (Fig. 3a, b)<sup>34</sup>. Thus, IL-6 and TGF $\beta$  play specific and unique roles in thymic T<sub>H</sub>-17 development. Previous work identified IFN- $\gamma$  as a negative regulator of IL-17 production<sup>35</sup>. It is unclear, however, if this cytokine inhibits differentiation of T<sub>H</sub>-17 cells or regulates IL-17 production following differentiation. To address this issue we bred DTg mice to animals genetically lacking IFN- $\gamma$ . These mice showed similar T<sub>H</sub>-17 populations in the thymus or LN as IFN- $\gamma$ -intact DTg animals (Fig. 3c). On the other hand, LN CD4<sup>+</sup> T cells from *Ifng*<sup>-/-</sup> DTg mice produced significantly more IL-17 after culture with PCC than did *Ifng*<sup>+/+</sup> DTg LN CD4<sup>+</sup> T cells (Fig. 3d). Addition of IFN- $\gamma$  to such cultures resulted in a dose dependent decrease in IL-17 secretion (Fig. 3e). Thus, whereas IL-6 and TGF- $\beta$  influence T<sub>H</sub>-17 differentiation in the thymus, IFN- $\gamma$  appears to regulate these cells once differentiated and has the potential to down-modulate IL-17 production during the course of an inflammatory response.

### DTg T<sub>H</sub>-17 cells express ICOS but not PD-1

Compared to STg or wild-type animals, the majority of CD4<sup>+</sup> T cells including both the T<sub>H</sub>-17 and T<sub>H</sub>1 populations in DTg mice expressed CD44, a marker of activated or memory T cells (Fig. 1b, 4a). However, compared to the T<sub>H</sub>1 subset, T<sub>H</sub>-17 cells in DTg mice expressed higher amounts of the inducible costimulator (ICOS), a member of the CD28 superfamily and an important indicator of T cell activation<sup>36</sup>. This observation suggests a difference in basal activation status of T<sub>H</sub>1 and T<sub>H</sub>-17 subsets in DTg mice (Fig. 4b). By contrast, PD-1, an established negative regulator of T cells<sup>37</sup>, was expressed in lower amounts on T<sub>H</sub>-17 than on T<sub>H</sub>1 cells (Fig. 4c). This protein functionally distinguishes these two populations, as *in vitro* antibody-mediated blockade of PD-1 ligand enhanced PCC-induced production of IFN- $\gamma$  but had little effect on IL-17 production (Fig. 4d).

### Migration of DTg T<sub>H</sub>-17 cells

In DTg mice, T<sub>H</sub>-17 cells were enriched in the liver, lungs, Peyer's patches (PP) and the lamina propria (LP) compared to the spleen (Fig. 5a). In contrast, IFN- $\gamma$ -producing cells preferentially populated the spleen and liver (Fig. 5a). To confirm that T<sub>H</sub>-17 cells had specific migration patterns compared to non-IL-17 secreting populations, we purified total CD4<sup>+</sup> T cells from the spleen and LN of DTg mice, labeled them with the intracellular fluorescent dye CFSE, and transferred them to wild-type recipients. Two days following transfer, we found that, compared to CD4<sup>+</sup> T cells lacking the capacity to produce IL-17,

those that made this cytokine had the greatest relative recruitment to the LP followed by the lungs, liver, LN, and then the spleen (Fig. 5b). We noted a different migration pattern of IFN- $\gamma$ -producing cells (Supplementary Fig. 6a). Of note, the transferred cells did not proliferate at these sites, indicating that their accumulation was due to migration and not local population expansion (Supplementary Fig. 6b).

Given this pattern of migration, we asked if T<sub>H</sub>-17 cells isolated from spleens of DTg mice displayed unique markers allowing selected peripheral homing<sup>38</sup>. The majority of DTg T<sub>H</sub>-17 cells expressed  $\alpha 4\beta 1$  integrins, with heterogeneous expression of  $\beta 7$  and  $\alpha IEL$  but minimal expression of  $\alpha 1$  (Fig. 5c). In addition, chemokine receptor analysis revealed that the T cell compartment of DTg mice contained CD4<sup>+</sup> T cells expressing CCR3, CCR5, CCR6 (<http://www.signaling-gateway.org/molecule/query?afcsid=A000629>), CCR9, CCR10 and CXCR3. Further inspection indicated that DTg T<sub>H</sub>-17 cells uniquely expressed CCR6, an established T<sub>H</sub>-17 cell associated chemokine receptor<sup>39</sup>, but did not express any other inflammatory chemokine receptors tested (Fig. 5d). These findings are consistent with DTg T<sub>H</sub>-17 cell homing to liver and lung, as these are sites of basal expression of CCL20, the ligand for CCR6<sup>47</sup>.

### DTg T<sub>H</sub>-17 cells express ROR $\gamma$ t, IL-23R and IL-22

We next asked if self-reactive T<sub>H</sub>-17 cells that develop intrathymically in the absence of inflammation share features with previously described T<sub>H</sub>-17 cells<sup>5, 9, 41, 42</sup>. We sorted CD4<sup>+</sup> T cells from LN and spleens of DTg mice into T<sub>reg</sub>, T<sub>H</sub>1 and T<sub>H</sub>-17 populations based upon expression of CD44, CD25, ICOS, and CCR6; we also sorted naïve CD25<sup>lo</sup> CD44<sup>lo</sup> cells. Intracellular cytokine staining and RT-PCR for IL-17 and IFN- $\gamma$  confirmed the validity of this sorting strategy (Supplementary Fig. 7). The T<sub>H</sub>-17 population uniquely expressed transcripts encoding ROR $\gamma$ t (*Rorc*), IL-23R and IL-22; in contrast *Il10* transcripts were expressed only in the T<sub>reg</sub> subset (Fig. 6a). Using the same sorting strategy for thymocytes from DTg mice (Supplementary Fig. 8a), we found that ROR $\gamma$ t, IL-23R and IL-22 were also unique to the thymic T<sub>H</sub>-17 subset (Supplementary Fig. 8b). This subset also expressed high amounts of *Rag1* mRNA, comparable to CD4 SP thymocytes that lacked CD44 expression, and roughly 50-fold higher than LN cells (Supplementary Fig. 8c). Cultures of splenocytes confirmed that DTg T cells produced IL-22 in an antigen-dependent manner (Fig. 6b), and that cells producing this cytokine were also present in the thymus of DTg mice (Fig. 6c). Thus, thymic T<sub>H</sub>-17 cells obtained from DTg mice express lineage features of T<sub>H</sub>-17 cells that have been previously found upon *in vitro* skewing and in inflammatory models.

### DTg T<sub>H</sub>-17 cells suppress hepatic inflammation via IL-22

To determine if AND TCR Tg T cells that produce IL-17 and IL-22 in response to self-antigen were functional, we assessed their effect in a model of toxin-induced hepatitis<sup>43</sup>. CD4<sup>+</sup> T cells were purified from DTg mice, depleted of T<sub>reg</sub> cells and transferred to PCC-expressing or wild-type recipients. Forty-eight hours later, we exposed recipient mice to the hepatic toxin D-(+)-galactosamine (GalN) in the presence of lipopolysaccharide (LPS). Transfer of DTg T cells protected mice from the toxic effects of GalN and LPS, as evidenced by reduction in hepatic enzyme concentrations; the beneficial effect of DTg cells

was enhanced by expression of PCC in the recipient mice (Fig. 6d). An IL-22 blocking antibody abrogated the protective effect of DTg cells during hepatitis induction, whereas IL-22 blockade in the absence of DTg cells had no effect (Fig. 6e, Supplementary Fig. 9). Thus, IL-22 produced by self-reactive DTg cells can suppress inflammation-induced liver toxicity.

### Thymic T<sub>H</sub>-17 cells in wild-type mice

Finally, to demonstrate that our findings were not merely an artifact of double transgenic models, we sought to identify IL-17 producing cells in peripheral lymphoid organs and thymi of wild-type mice. Within the LN, the overall T<sub>H</sub>-17 population was small but made up over 3% of the CD4<sup>+</sup>CD44<sup>+</sup> T cells (Fig. 7a). These cells were unique in their CCR6 and ICOS expression (Fig. 7b), analogous to the T<sub>H</sub>-17 population identified in DTg mice. IL-17 producing CD4 SP thymocytes were also identified in wild-type mice (Fig. 7c), and were characterized by reduced TCRβ expression (Fig. 7d), consistent with self-reactivity. Thymic T<sub>H</sub>-17 cells also expressed GFP regulated by the *Rag2* promoter<sup>29</sup> (Fig. 7e), consistent with a thymic origin. IL-17<sup>+</sup> thymocytes in wild-type mice, like those in DTg animals, expressed ICOS and CCR6 (Fig. 7f, Supplementary Fig. 8a). Using these latter two markers, we were able to employ the same sorting strategy as for DTg thymocytes (Supplementary Fig. 8a) to isolate IL-17-producing thymocytes from wild-type mice and confirm that they selectively expressed *Rorc*, *Il23r*, and *Il22* mRNA (Fig. 7g). We also observed this population in CD1d-deficient mice, demonstrating that they were not invariant natural killer T cells<sup>44</sup> (Supplementary Fig. 10a–d). Thus, IL-17<sup>+</sup> thymocytes and CD4<sup>+</sup> T cells exist in wild-type mice even in the absence of inflammation.

## DISCUSSION

Our work suggests that the current understanding of T<sub>H</sub>-17 cell differentiation needs to be expanded to include development in the thymus. We found IL-17<sup>+</sup> thymocytes in two DTg models, in significantly (log fold) higher percentages and numbers than in STg controls. We also detected small populations of IL-17<sup>+</sup> thymocytes in wild-type mice. Several experiments excluded the possibility that IL-17<sup>+</sup> thymocytes originated in and recirculated from the periphery. In addition, DTg mice did not have an intrinsically heightened inflammatory environment that might spontaneously promote T<sub>H</sub>-17 differentiation in the periphery.

Thymic T<sub>H</sub>-17 cells were selected based on increased reactivity to self-antigens in DTg mice, and produced IL-17 and IL-22 upon stimulation with neoself-antigen. Although we are uncertain if endogenous TCR rearrangement plays a role in the development of these cells, the presence of IL-17<sup>+</sup> splenocytes and thymocytes in *Rag1*<sup>-/-</sup> DTg mice indicates that they can arise in the absence of such rearrangements. Thymic IL-17-producing cells in wild-type mice express lower amounts of surface TCRβ than other thymic populations, also suggestive of a self-reactive phenotype.

These findings extend the function of self-antigen presentation during thymic development from one originally thought to be limited to positive selection of functional T cells followed by deletion of autoreactive cells, a concept expanded more recently to include selection of

$T_{reg}$  21, 22, NKT23, CD8 $\alpha\alpha^{+24}$ , and  $\gamma\delta$  T25 cells. These observations also strengthen the existing link between the development of  $T_H$ -17 cells and natural  $T_{reg}$  cells, although it is important to emphasize that the thymic  $T_H$ -17 cells we describe exhibited effector programming similar to non-classical effector T cell populations, including  $\gamma\delta$  and NK T cells. These two lineages offer a paradigm of how inherently self-reactive cells with rearranged TCRs can assist the innate immune system in host responses via recognition of self-ligands, and play a non-redundant role in clearance of pathogens<sup>45, 46</sup> and/or down-modulation of inflammatory injury<sup>47, 48</sup>. Indeed, the thymic  $T_H$ -17 cells we describe closely resemble  $\gamma\delta$  T cells with regard to effector function in that they share IL-17 as a proinflammatory mediator<sup>49</sup> and have the potential to modulate peripheral inflammatory responses despite numerical inferiority compared to conventional effector T cells.  $\gamma\delta$  T cells can be activated upon recognition of self-ligands that are upregulated in the periphery during inflammation (e.g. non-classical major histocompatibility complex class I molecules T10 and T2250). Thymic  $T_H$ -17 cells suppressed hepatic inflammation via IL-22 secretion promoted by neoself-antigen recognition. Thus, effector capability upon self-antigen recognition in peripheral inflammatory responses reflects an already established paradigm.

Thymus-derived  $T_H$ -17 cells seeded peripheral organs, with enrichment in the LP, liver, lung, and PP in DTg animals. While it is formally possible that such cells arose as a consequence of differentiation in secondary lymphoid organs, as noted above several lines of evidence suggest that this is not the case. In addition, the phenotype of the thymic  $T_H$ -17 cells (expression of  $\alpha 4\beta 1$  integrins and CCR6) favors their migration to such sites as the lung and liver<sup>40</sup>.

Additional work is needed to determine if thymic  $T_H$ -17 cells, like previously described  $T_H$ -17 cells, make IL-17F; this cytokine may exert immunoregulatory functions in allergic responses<sup>51</sup>. Thus the thymic  $T_H$ -17 population that migrates to the lung may protect the host against allergic lung injury via IL-17F secretion. The balance between secretion of cytokines with pro- and anti-inflammatory potential, in concert with the tissue-specific expression of their receptors, presumably would resolve the paradox of a self-reactive population that can secrete cytokines having either property. Accordingly, it is likely that IL-17 production is carefully regulated so that its production is restricted to situations demanding inflammation. Simultaneous production of a potentially protective cytokine such as IL-22 may promote survival of cells expressing IL-22R during highly toxic inflammation that thymic  $T_H$ -17 cells help create<sup>52</sup>. At the same time, secretion of IL-22 would not necessarily subjugate the pro-inflammatory function of IL-17 given the lack of IL-22R expression on immune cells.

Unexpectedly, basal IL-6 concentrations, in the absence of obvious inflammation in DTg mice, determined the size of the thymic  $T_H$ -17 population. Although the source(s) of cytokines required for thymic  $T_H$ -17 cell development is not yet clear, it is intriguing to postulate that during inflammation, IL-6 produced following innate cell activation in the periphery operates in a feedback loop on the thymus to enhance production of  $T_H$ -17 cells at the expense of natural  $T_{reg}$  cells. In an analogous regulatory loop, natural  $T_{reg}$  cells in the thymus<sup>53</sup> might regulate thymic  $T_H$ -17 development. Thymic  $T_H$ -17 cells depend upon TGF $\beta$  for optimal development; a possible source of this cytokine is natural  $T_{reg}$  cells. We



propose that during early T cell development, thymic IL-2 concentrations continue to rise with the expanding mature T cell compartment reaching a critical abundance around day 3, allowing for T<sub>reg</sub> cell skewing from the self-reactive compartment<sup>13</sup>. As the T<sub>reg</sub> population expands, it serves as an IL-2 sink to lift restriction of T<sub>H</sub>-17 lineage commitment by this cytokine<sup>14</sup>, and produces TGFβ to promote T<sub>H</sub>-17 differentiation. Thus, the environment may directly regulate the balance between development of T<sub>reg</sub> and T<sub>H</sub>-17 subsets from a common precursor. As such, T<sub>reg</sub> enrichment of the type we observed in DTg mice may be a necessary component of natural T<sub>H</sub>-17 development.

Rapid effector capability and self-reactivity may explain why the thymic T<sub>H</sub>-17 population has been preserved in an immune system that also has induced IL-17 producing cells that recognize foreign antigens. Thymic T<sub>H</sub>-17 cells in DTg mice have a TCR signaling threshold set at least a log fold above TCR STg cells, suggesting that activation of the former is limited to conditions with elevated self-antigen presentation such as during pathogen challenge with associated tissue injury. If present in wild-type mice, such a phenotype presumably would enable the thymic subset to evaluate the severity of infection by amount of tissue destruction, and upon presentation of self-peptides, resident self-reactive T<sub>H</sub>-17 cells could promote a robust response, including rapid neutrophil recruitment. Thus, the T<sub>H</sub>-17 subset would be capable of directing the immune response according to the severity of infection, with host protection mediated by IL-22 whose effects are restricted to non-immune cells<sup>52</sup>. While the evolutionary retention of the thymic IL-17 producing subset indicates an overall host benefit, its careful regulation can presumably be delinquent given the appropriate environmental trigger in a genetically susceptible individual.

## ONLINE METHODS

### Mice

AND mice expressing the transgenic V<sub>α</sub>11V<sub>β</sub>3 TCR that recognizes PCC<sub>88–104</sub>, and ePCC mice that express PCC27 were originally provided by S. Hedrick (University of California, San Diego) and were maintained in the B10.BR background. We produced CD90.1 wild-type mice, and AND × PCC DTg, AND STg and ePCC STg animals lacking IL-6 or IFN-γ on the B10.BR background by serial backcross to the C57BL/6J-*IghaThy1aGp1a*, B6.129S2-*Il6*<sup>tm1Kopf/J</sup>, and B6.129S7-*Ifng*<sup>tm1Ts/J</sup> backgrounds, respectively (all from The Jackson Laboratory). OTII (C57BL/6-Tg(TcraTcrb)425Cbn/J), Act-mOVA (C57BL/6-Tg(ACTB-OVA)916Jen/J), B6.129S-*Rag1*<sup>tm1Mom</sup>, CD1d-deficient (C.129S2-*Cd1*<sup>tm1Gru/J</sup>), BALB/cJ, and C57BL/6 mice were purchased from The Jackson Laboratory. We produced OTII (C57BL/6-Tg(TcraTcrb)425Cbn/J) and Act-mOVA (C57BL/6-Tg(ACTB-OVA)916Jen/J) animals lacking RAG1 by serial backcross to the B6.129S-*Rag1*<sup>tm1Mom</sup> background. RAG2:GFP mice<sup>29</sup>, kindly provided by F. Alt (The Children's Hospital and Harvard Medical School, Boston, MA), and transgenic CD4dnTGFβRII mice<sup>33</sup> were backcrossed to B10.BR AND × PCC DTg mice for at least 3 generations, and were selected for H-2<sup>k</sup> homozygosity. TA.TIM mice<sup>30</sup> on the B10.BR background were kindly provided by H. van Santen, D. Mathis, and C. Benoist (Joslin Diabetes Center and Harvard Medical School, Boston, MA). Animals were identically housed in specific pathogen-free facilities at

the Yale Animal Resources Center. The Institutional Animal Care and Use Committee at the Yale School of Medicine approved all experiments.

### Isolation of cells, cell cultures and proliferation assays

Splenocytes, lymphocytes, and thymocytes were obtained by disrupting organs of 6- to 8-week-old mice and were depleted of erythrocytes by hypotonic lysis. Cell cultures were performed in Click's media supplemented with 10% Fetalplex (Gemini Bio-products), 2mM glutamine, 100 Iu/ml penicillin, 0.1 mg/ml streptomycin (Gibco) and 2  $\mu$ M  $\beta$ -mercaptoethanol. CD4<sup>+</sup> T cells were isolated using EasySep mouse CD4<sup>+</sup> enrichment kit (Stem Cell Technologies) according to the manufacturer's instructions. T cell-depleted splenocytes were obtained using an EasySep CD90.2 positive selection kit (Stem Cell Technologies) and the unlabelled fraction was used for cultures. CD4<sup>+</sup> T cells, labeled via incubation with 2.5 $\mu$ M of the intracellular dye 5,6-carboxyfluorescein diacetate succinimidyl ester (CFSE, Molecular Probes) for 10 min at 37°, and T cell-depleted splenocytes were cultured in a 1:1 ratio at 1  $\times$  10<sup>6</sup> cells/ml and stimulated with PCC<sub>88-104</sub> (10 $\mu$ g/ml) for 3 days. Supernatants were collected at day 3 and cytokines were measured. The proliferation index was calculated as the average number of cell divisions of responding cells (ignores peak 0). For isolation of cells from the lung and liver, mice were sacrificed and their cardiac ventricles perfused with PBS. Organs were diced, incubated in 100 U/ml collagenase (Gibco) at 37° for 1 h and then passed through a 70 $\mu$ m cell strainer and cells separated by 44:56 Percoll gradient.

### Hepatitis induction and T cell transfers

Following T<sub>reg</sub> cell depletion using biotin-conjugated anti-CD25 (PC61), 6–8  $\times$  10<sup>6</sup> purified splenic and LN CD4<sup>+</sup> T cells were injected intravenously (i.v.) into recipient mice. Two days later, animals were given 10mg D-(+)-galactosamine (Sigma) and 300ng LPS from *Escherichia coli* 055:B5 (Sigma) i.v. in 200 $\mu$ l PBS. When using B10.BR  $\times$  PCC mice as recipients, an additional 100 $\mu$ g of PCC<sub>88-104</sub> peptide was injected with the hepatotoxin. We measured serum ALT concentrations (Teco Diagnostics) five hours later. For IL-22 blockade, 50 $\mu$ g anti-mouse IL-22 polyclonal antibody (R&D Systems) was i.v. injected in 200  $\mu$ l PBS 2 hours prior to hepatitis induction.

### Flow cytometry

For intracellular cytokine staining, cells were stimulated for 2 hours with 50 ng/ml phorbol myristate acetate (PMA) and 1  $\mu$ g/ml ionomycin (Sigma-Aldrich) in the presence of brefeldin A (GolgiPlug, BD Biosciences). Surface staining with indicated antibodies in the presence of Fc-blocking antibodies was followed by fixation in 1% formaldehyde for 20 min and intracellular staining using the Perm/Wash reagent (BD Biosciences) as directed. All samples were analyzed with FACSCalibur or LSRII (Becton Dickinson) instruments. Flow cytometry data was analyzed with FloJo 8.2 (Tree Star) software. All antibodies were from BD Biosciences, except for those directed against CD25 (PC61.5), CCR9(CW-1.2), FoxP3 (FJK-16s),  $\beta$ 1 (HM $\beta$ 1-1), IL-17 (17B7), PD-L1 (MIH5) (all from eBioscience), CXCR3 (FAB1685P) and CCR10 (248918) (both from R&D Systems),  $\alpha$ 1 (HM $\alpha$ 1) (Abcam), and GFP (600-302-215) (Rockland); for analysis of GFP and IL-17 expression, cells were

stimulated as described above with PMA and ionomycin. For analysis of wild-type LN and thymi, single cell suspensions were first enriched for CD4<sup>+</sup> T cells and then labeled with antibodies.

### Measurement of cytokines, chemokines and antibodies

Supernatants were collected after 3 days of culture and IL-2, IL-17, IFN- $\gamma$ , and IL-4 concentrations were measured by Bio-Plex (Bio-Rad). IL-22 was detected using ELISA (Antigenix America). Serum cytokines and chemokines were detected by a 9-Plex Bio-Plex consisting of IL-1 $\alpha$ , IL-6, IL-10, IL-17, IFN- $\gamma$ , MIP-1 $\alpha$ , IL-12(p40), RANTES, and TNF (Bio-Rad). Total serum IgM was measured by sandwich ELISA using anti-IgM capture antibodies (II-41) (BD Bioscience) and isotype-specific detection Abs conjugated to HRP (Southern Biotechnology Associates). For detection of anti-DNA antibodies, plates were coated with BSA, then dsDNA (Sigma), and developed using isotype-specific detection Abs (F007-1241) (BD Bioscience).

### Q-PCR

Following cell sorting, RNA was isolated using an RNeasy mini kit (QIAGEN) and reverse transcribed into cDNA with iScript cDNA synthesis kit (Bio-Rad). Expression was determined using primers listed (Supplementary Table 2) and normalized to *Actb* or *Hprt1*.

### Statistical analysis

Data are presented as mean  $\pm$  s.e.m. and were analyzed with Student's t-test using Prism4 (GraphPad Software).

### Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

### ACKNOWLEDGEMENTS

We are grateful to S. Hedrick and S. Oehan for providing the AND and PCC transgenic mice, F. Alt and D. Schatz for the RAG2:GFP mice, H. van Santen, D. Mathis and C. Benoist for TA.TIM mice, and L. Bockenstedt for supplying the CD1d-deficient animals. We also thank E. Marks and other members of the Craft lab for helpful discussions and L. Zenewicz and E. Espluges for advice. R. Medzhitov and S. Kaech graciously served as critical readers of the manuscript. We also acknowledge those investigators whose work we could not cite because of space limitations. This work was supported by NIH Grants AR40072, AR44076, AI56219, and AR053495, and grants from the Arthritis Foundation, Rheuminations, Inc., and the Connecticut Chapter of the Lupus Foundation. B. Marks was supported by NIH MSTP TG 5T32GM07205.

### REFERENCES

1. Murphy KM, Reiner SL. The lineage decisions of helper T cells. *Nat Rev Immunol.* 2002; 2:933–944. [PubMed: 12461566]
2. Abbas AK, Murphy KM, Sher A. Functional diversity of helper T lymphocytes. *Nature.* 1996; 383:787–793. [PubMed: 8893001]
3. Harrington LE, Mangan PR, Weaver CT. Expanding the effector CD4 T-cell repertoire: the Th17 lineage. *Curr Opin Immunol.* 2006; 18:349–356. [PubMed: 16616472]
4. Aggarwal S, Ghilardi N, Xie MH, de Sauvage FJ, Gurney AL. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. *J Biol Chem.* 2003; 278:1910–1914. [PubMed: 12417590]

5. Ivanov, et al. The orphan nuclear receptor ROR $\gamma$  directs the differentiation program of proinflammatory IL-17<sup>+</sup> T helper cells. *Cell*. 2006; 126:1121–1133. [PubMed: 16990136]
6. Yang XO, et al. T helper 17 lineage differentiation is programmed by orphan nuclear receptors ROR $\alpha$  and ROR $\gamma$ . *Immunity*. 2008; 28:29–39. [PubMed: 18164222]
7. Zenewicz LA, et al. Interleukin-22 but not interleukin-17 provides protection to hepatocytes during acute liver inflammation. *Immunity*. 2007; 27:647–659. [PubMed: 17919941]
8. Langrish CL, et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. *J Exp Med*. 2005; 201:233–240. [PubMed: 15657292]
9. Bowman EP, Chackerian AA, Cua DJ. Rationale and safety of anti-interleukin-23 and anti-interleukin-17A therapy. *Curr Opin Infect Dis*. 2006; 19:245–252. [PubMed: 16645485]
10. Bettelli E, et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. *Nature*. 2006; 441:235–238. [PubMed: 16648838]
11. Mangan PR, et al. Transforming growth factor- $\beta$  induces development of the T(H)17 lineage. *Nature*. 2006; 441:231–234. [PubMed: 16648837]
12. Veldhoen M, Hocking RJ, Atkins CJ, Locksley RM, Stockinger B. TGF $\beta$  in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. *Immunity*. 2006; 24:179–189. [PubMed: 16473830]
13. Setoguchi R, Hori S, Takahashi T, Sakaguchi S. Homeostatic maintenance of natural Foxp3(+) CD25(+) CD4(+) regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization. *J Exp Med*. 2005; 201:723–735. [PubMed: 15753206]
14. Laurence A, et al. Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation. *Immunity*. 2007; 26:371–381. [PubMed: 17363300]
15. Kryczek I, et al. Cutting edge: opposite effects of IL-1 and IL-2 on the regulation of IL-17<sup>+</sup> T cell pool IL-1 subverts IL-2-mediated suppression. *J Immunol*. 2007; 179:1423–1426. [PubMed: 17641006]
16. Xu L, Kitani A, Fuss I, Strober W. Cutting edge: regulatory T cells induce CD4<sup>+</sup>CD25<sup>+</sup>Foxp3<sup>+</sup> T cells or are self-induced to become Th17 cells in the absence of exogenous TGF- $\beta$ . *J Immunol*. 2007; 178:6725–6729. [PubMed: 17513718]
17. Mucida D, et al. Reciprocal TH17 and regulatory T cell differentiation mediated by retinoic acid. *Science*. 2007; 317:256–260. [PubMed: 17569825]
18. Zhou L, et al. TGF- $\beta$ -induced Foxp3 inhibits T(H)17 cell differentiation by antagonizing ROR $\gamma$  function. *Nature*. 2008; 453:236–240. [PubMed: 18368049]
19. Zhang F, Meng G, Strober W. Interactions among the transcription factors Runx1, ROR $\gamma$  and Foxp3 regulate the differentiation of interleukin 17-producing T cells. *Nat Immunol*. 2008; 9:1297–1306. [PubMed: 18849990]
20. Gavin MA, et al. Foxp3-dependent programme of regulatory T-cell differentiation. *Nature*. 2007; 445:771–775. [PubMed: 17220874]
21. Jordan MS, et al. Thymic selection of CD4<sup>+</sup>CD25<sup>+</sup> regulatory T cells induced by an agonist self-peptide. *Nat Immunol*. 2001; 2:301–306. [PubMed: 11276200]
22. Hsieh CS, Zheng Y, Liang Y, Fontenot JD, Rudensky AY. An intersection between the self-reactive regulatory and nonregulatory T cell receptor repertoires. *Nat Immunol*. 2006; 7:401–410. [PubMed: 16532000]
23. Kronenberg M, Gapin L. The unconventional lifestyle of NKT cells. *Nat Rev Immunol*. 2002; 2:557–568. [PubMed: 12154375]
24. Cheroutre H. Starting at the beginning: new perspectives on the biology of mucosal T cells. *Annu Rev Immunol*. 2004; 22:217–246. [PubMed: 15032579]
25. Xiong N, Raulet DH. Development and selection of gammadelta T cells. *Immunol Rev*. 2007; 215:15–31. [PubMed: 17291276]
26. Apostolou I, Sarukhan A, Klein L, von Boehmer H. Origin of regulatory T cells with known specificity for antigen. *Nat Immunol*. 2002; 3:756–763. [PubMed: 12089509]
27. Oehen S, Feng L, Xia Y, Surh CD, Hedrick SM. Antigen compartmentation and T helper cell tolerance induction. *J Exp Med*. 1996; 183:2617–2626. [PubMed: 8676082]

28. Grossman Z, Paul WE. Autoreactivity, dynamic tuning and selectivity. *Curr Opin Immunol.* 2001; 13:687–698. [PubMed: 11677091]
29. Monroe RJ, et al. RAG2:GFP knockin mice reveal novel aspects of RAG2 expression in primary and peripheral lymphoid tissues. *Immunity.* 1999; 11:201–212. [PubMed: 10485655]
30. van Santen HM, Benoist C, Mathis D. Number of T reg cells that differentiate does not increase upon encounter of agonist ligand on thymic epithelial cells. *J Exp Med.* 2004; 200:1221–1230. [PubMed: 15534371]
31. Li MO, Wan YY, Flavell RA. T cell-produced transforming growth factor-beta1 controls T cell tolerance and regulates Th1- and Th17-cell differentiation. *Immunity.* 2007; 26:579–591. [PubMed: 17481928]
32. Veldhoen M, Hocking RJ, Flavell RA, Stockinger B. Signals mediated by transforming growth factor-beta initiate autoimmune encephalomyelitis, but chronic inflammation is needed to sustain disease. *Nat Immunol.* 2006; 7:1151–1156. [PubMed: 16998492]
33. Gorelik L, Flavell RA. Abrogation of TGFbeta signaling in T cells leads to spontaneous T cell differentiation and autoimmune disease. *Immunity.* 2000; 12:171–181. [PubMed: 10714683]
34. Fahlen L, et al. T cells that cannot respond to TGF-beta escape control by CD4(+)CD25(+) regulatory T cells. *J Exp Med.* 2005; 201:737–746. [PubMed: 15753207]
35. Park H, et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. *Nat Immunol.* 2005; 6:1133–1141. [PubMed: 16200068]
36. Yoshinaga SK, et al. T-cell co-stimulation through B7RP-1 and ICOS. *Nature.* 1999; 402:827–832. [PubMed: 10617205]
37. Nishimura H, Nose M, Hiai H, Minato N, Honjo T. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM 38.
38. Ley K, Laudanna C, Cybulsky MI, Nourshargh S. Getting to the site of inflammation: the leukocyte adhesion cascade updated. *Nat Rev Immunol.* 2007; 7:678–689. [PubMed: 17717539]
39. Reboldi A, et al. C-C chemokine receptor 6-regulated entry of TH-17 cells into the CNS through the choroid plexus is required for the initiation of EAE. *Nat Immunol.* 2009; 10:514–523. [PubMed: 19305396]
40. Schutyser E, Struyf S, Van Damme J. The CC chemokine CCL20 and its receptor CCR6. *Cytokine Growth Factor Rev.* 2003; 14:409–426. [PubMed: 12948524]
41. Liang SC, et al. Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. *J Exp Med.* 2006; 203:2271–2279. [PubMed: 16982811]
42. McGeachy MJ, et al. TGF-beta and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain T(H)-17 cell-mediated pathology. *Nat Immunol.* 2007; 8:1390–1397. [PubMed: 17994024]
43. Arvelo MB, et al. A20 protects mice from D-galactosamine/lipopolysaccharide acute toxic lethal hepatitis. *Hepatology.* 2002; 35:535–543. [PubMed: 11870365]
44. Michel ML, et al. Critical role of ROR-gammat in a new thymic pathway leading to IL-17-producing invariant NKT cell differentiation. *Proc Natl Acad Sci U S A.* 2008; 105:19845–19850. [PubMed: 19057011]
45. Mattner J, et al. Exogenous and endogenous glycolipid antigens activate NKT cells during microbial infections. *Nature.* 2005; 434:525–529. [PubMed: 15791258]
46. Hayday A, Tigelaar R. Immunoregulation in the tissues by gammadelta T cells. *Nat Rev Immunol.* 2003; 3:233–242. [PubMed: 12658271]
47. Lahn M, et al. Negative regulation of airway responsiveness that is dependent on gammadelta T cells and independent of alphabeta T cells. *Nat Med.* 1999; 5:1150–1156. [PubMed: 10502818]
48. Jahng AW, et al. Activation of natural killer T cells potentiates or prevents experimental autoimmune encephalomyelitis. *J. Exp. Med.* 2001; 194:1789–1799. [PubMed: 11748280]
49. Roark CL, Simonian PL, Fontenot AP, Born WK, O'Brien RL. gammadelta T cells: an important source of IL-17. *Curr Opin Immunol.* 2008; 20:353–357. [PubMed: 18439808]
50. Chien YH, Konigshofer Y. Antigen recognition by gammadelta T cells. *Immunol Rev.* 2007; 215:46–58. [PubMed: 17291278]


51. Yang XO, et al. Regulation of inflammatory responses by IL-17F. *J Exp Med.* 2008; 205:1063–1075. [PubMed: 18411338]
52. Aggarwal S, Xie MH, Maruoka M, Foster J, Gurney AL. Acinar cells of the pancreas are a target of interleukin-22. *J Interferon Cytokine Res.* 2001; 21:1047–1053. [PubMed: 11798462]
53. Ito T, et al. Two functional subsets of FOXP3+ regulatory T cells in human thymus and periphery. *Immunity.* 2008; 28:870–880. [PubMed: 18513999]

Author Manuscript


Author Manuscript

Author Manuscript

Author Manuscript




**Figure 1.** IL-17<sup>+</sup> cells are enriched in peripheral lymphoid organs of AND x PCC DTg mice. (a–c) Splenocytes from indicated mice were analyzed by flow cytometry for percentages of CD4<sup>+</sup> T cells (a), activated (CD44<sup>hi</sup>, CD62L<sup>lo</sup>) TCRβ<sup>+</sup>CD4<sup>+</sup> cells (b), and CD4<sup>+</sup>FoxP3<sup>+</sup> cells (c). (d) CFSE-labeled CD4<sup>+</sup> T cells were cultured with T cell-depleted splenocytes plus the indicated dose of PCC peptide<sub>88–104</sub> (left 2 panels). Proliferation profile and proliferation index was measured by CFSE dilution (proliferation index is the average number of divisions of a dividing cell, ignores peak 0). (e) Cytokines in supernatants from cultures of CD4<sup>+</sup> T cells and T cell-depleted splenocytes plus 10 μg/ml PCC peptide<sub>88–104</sub> were analyzed by ELISA (\* *P* < 0.05). (f,g) The percent of IL-17<sup>+</sup> compared to IFN-γ<sup>+</sup> (f) or IL-17<sup>+</sup> versus FoxP3<sup>+</sup> splenic TCRβ<sup>+</sup>CD4<sup>+</sup> T cells (g) was assessed by intracellular staining. (h) The percentages of IL-17<sup>+</sup>, IFN-γ<sup>+</sup> and FoxP3<sup>+</sup> cells among TCRβ<sup>+</sup>CD4<sup>+</sup> populations from spleens of DTg (gray bars) and STg (black bars) mice were compared (3 mice in each group; \* *P* < 0.05). Data in all panels are representative of at least 3 independent experiments.




**Figure 2.**

TH-17 cells develop in the thymus. (a,b) Intracellular staining was used to determine percentages of IL-17<sup>+</sup>, FoxP3<sup>+</sup> and IFN-γ<sup>+</sup> cells among TCRβ<sup>+</sup>CD4<sup>+</sup>CD8<sup>-</sup> thymocytes and splenocytes in DTg and STg mice. Left, representative dot plots. Right, graph showing mean ± s.e.m. of 3 mice in each group. (\* *P* < 0.05) (c,d) TCRβ<sup>+</sup>CD4<sup>+</sup>CD8<sup>-</sup>HSA<sup>+</sup> thymocytes and TCRβ<sup>+</sup>CD4<sup>+</sup> splenocytes from DTg mice were cultured for 3 d with T cell-depleted splenocytes loaded with 10μg/ml PCC peptide<sub>88-104</sub>. IL-17 production was analyzed by ELISA (e) and intracellular staining (d). (e) GFP expression in indicated thymocyte subsets from DTg RAG2:GFP mice was measured using flow cytometry. CD4<sup>+</sup>CD8<sup>+</sup> double positive (DP) thymocytes and CD4<sup>+</sup> splenocytes were used as positive and negative controls, respectively. (f) Purified CD4<sup>+</sup> DTg splenic and LN T cells labeled with CFSE were transferred to wild-type recipients; five days post-transfer, percentages of CFSE<sup>+</sup> T cells in the LN, liver, lungs and thymi of recipient mice were determined (3 mice per group). (g) Percentages and absolute numbers of IL-17<sup>+</sup>, and percentage of IFN-γ<sup>+</sup> TCRβ<sup>+</sup>CD4<sup>+</sup> cells within the thymi and LN of AND × TA.TIM (TTg), AND STg and wild-type mice were determined by flow cytometry and cell counting. \* *P* < 0.05 comparing TTg to STg; 6 TTg, 4 STg, and 5 wild-type mice were analyzed. Data are representative of 3 (a,b,g) or 2 (c-f) independent experiments.







**Figure 3.** Thymic  $T_H$ -17 development depends upon basal IL-6 and TGF- $\beta$  production, whereas IFN- $\gamma$  is inhibitory during peripheral activation. **(a)** Percentages of TCR $\beta^+$ CD4 $^+$ CD8 $^-$ IL-17 $^+$  cells in thymi and LN of *Il6* $^{-/-}$  and CD4dnTGF $\beta$ RII (TGF $\beta$ RDN)40 mice were determined by flow cytometry. **(b)** The percentages of IL-17 $^+$ , IFN- $\gamma^+$ , and FoxP3 $^+$  cells among TCR $\beta^+$ CD4 $^+$ CD8 $^-$  thymocytes and splenocytes were compared between *Il6* $^{+/+}$  and *Il6* $^{-/-}$  DTg mice. **(c)** Percentages of TCR $\beta^+$ CD4 $^+$ CD8 $^-$ IL-17 $^+$  cells were determined in thymi and LN of *Ifng* $^{-/-}$  DTg mice. Graphs in **a–c** show mean  $\pm$  s.e.m. of a minimum of 3 mice of each genotype. \*  $P < 0.05$  **(d,e)** IL-17 in supernatants of splenocytes from DTg, STg and DTg *Ifng* $^{-/-}$  mice cultured with 10 $\mu$ g/ml PCC peptide $_{88-104}$  **(d, \*  $P < 0.05$ )** or from DTg mice cultured with peptide plus titrated doses of IFN- $\gamma$  **(e)**. Data are representative of 3 **(a,b)** or 2 **(c–e)** independent experiments.



**Figure 4.**

$T_H$ -17 cells from DTg mice express CD44, ICOS but not PD-1. (a–c) CD44, ICOS, and PD-1 were measured by flow cytometry on splenic IL-17<sup>+</sup> (black fill), IFN- $\gamma$ <sup>+</sup> (dotted gray) and total CD4<sup>+</sup> T cells (solid gray). In b, solid gray represents naïve CD4<sup>+</sup>CD44<sup>-</sup> cells. (d) Purified CD4<sup>+</sup> T cells from DTg mice were cultured for 3 d with T depleted splenocytes and 10 $\mu$ g/ml PCC peptide<sub>88–104</sub> in the presence of a range of concentrations of PD-L1 blocking antibody (clone MIH5). IL-17 and IFN- $\gamma$  in supernatants was measured by ELISA. Data are representative of 3 (a–c) or 2 (d) independent experiments.





**Figure 5.**

T<sub>H</sub>-17 cells from DTg mice express CCR6, integrins  $\alpha 4\beta 1$ , and are enriched in the lamina propria (LP), liver, lung, and Peyer's patches (PP). (a) Percentage of IL-17<sup>+</sup> or IFN- $\gamma$ <sup>+</sup> cells among TCR $\beta$ <sup>+</sup>CD4<sup>+</sup>CD8<sup>-</sup> cells from organs of DTg mice, as measured by intracellular staining (\*  $P$  0.05, \*\*  $P$  0.005 compared to spleen). Data represent results from a minimum of 3 mice. (b) Purified splenic and LN CD4<sup>+</sup> DTg T cells labeled with CFSE were transferred to wild-type recipients and percentages of IL-17<sup>+</sup> cells among CFSE<sup>+</sup>CD4<sup>+</sup> cells were measured in peripheral organs at two days post transfer (\*  $P$  0.05, \*\*  $P$  0.005). Data is composite of 3 separate transfer experiments, each using 4 mice per group, with data points combined for statistical analysis. (c) Surface expression of  $\alpha 4$ ,  $\beta 1$ ,  $\beta 7$ ,  $\alpha 1$  and  $\alpha IEL$  integrins on splenic CD4<sup>+</sup>IL-17<sup>+</sup> and CD4<sup>+</sup>IL-17<sup>-</sup> DTg cells and on CD4<sup>+</sup> STg cells was measured by flow cytometry. (d) Expression of CCR3, CCR5, CCR6, CCR9, CCR10 and


CXCR3 on CD4<sup>+</sup>IL-17<sup>+</sup>, CD4<sup>+</sup>IFN- $\gamma$ <sup>+</sup> and total CD4<sup>+</sup> T cells taken from DTg mice was measured by flow cytometry. Data are representative of 2 (**a**) or 3 (**c,d**) independent experiments.

Author Manuscript


Author Manuscript

Author Manuscript

Author Manuscript

**Figure 6.**

$T_H$ -17 cells from DTg mice produce IL-22 that promotes hepatocyte survival during inflammation. (a) Splenic and LN CD4<sup>+</sup> T cells were sorted into the indicates subsets, and mRNA transcripts were measured by Q-PCR, with the ratio of gene to  $\beta$ -actin expression determined by the relative quantification method ( $C_T$ ) (\*  $P < 0.05$ , compared to 3 other groups; \*\*  $P < 0.05$ , compared to naive). (b,c) IL-22 was measured by ELISA in supernatants of DTg splenocytes cultured for 3 d with increasing concentrations of PCC peptide<sub>88–104</sub> (b) and, along with IL-17, from cultures of CD4<sup>+</sup> splenocytes or thymocytes from DTg and STg mice cultured with 10 $\mu$ g/ml PCC peptide<sub>88–104</sub> (c). (\*  $P < 0.05$ , compared to concentrations from STg supernatants) (d,e) Serum aspartate aminotransferase (ALT) was measured in sera taken from mice 5 h post GalN+LPS treatment, with or without 48 h prior administration of CD25<sup>+</sup>-depleted CD4<sup>+</sup> T cells from DTg mice (d; \*  $P < 0.05$ ), and with or without 2 h pre-treatment with anti-IL-22 (e; \*  $P < 0.05$ ; ). Data are representative of 2 (b,c) or a combination of 3 (d,e) experiments, the latter totaling 12 mice per group, with data points combined for statistical analysis.



**Figure 7.**

TH-17 cells in LN and thymi of wild-type mice have a phenotype identical to TH-17 cells found in DTg mice. (a) Following CD4<sup>+</sup> T cell enrichment, TH-17 population size in LN of wild-type B10.BR mice was assessed by intracellular cytokine staining of TCRβ<sup>+</sup>CD4<sup>+</sup> or TCRβ<sup>+</sup>CD4<sup>+</sup>CD44<sup>+</sup> cells. (b) CCR6 and ICOS expression on the indicated subsets of LN cells of wild-type mice was measured by flow cytometry. (c) CD44 and IL-17 expression by TCRβ<sup>+</sup>CD4<sup>+</sup>CD8<sup>-</sup> thymocytes from wild-type B10.BR mice. (d) Expression of TCRβ on the indicated subsets from wild-type mice was measured by flow cytometry. (e) GFP expression in populations isolated from RAG2:GFP mice was evaluated using flow cytometry. Thymic TCRβ<sup>+</sup>DP cells and splenic TCRβ<sup>+</sup>CD4<sup>+</sup> cells were used as positive and negative controls, respectively. (f) CCR6 and ICOS expression on the indicated subsets from wild-type mice was measured by flow cytometry. Data (a–f) are representative of 3 independent experiments. (g) Thymocytes from wild-type mice were sorted into the indicated populations and mRNA transcripts were measured using Q-PCR, with the ratio of gene to *Hprt1* expression determined by the relative quantification method ( $-\Delta C_T$ ) (\* *P* 0.05; compared to 3 other groups, with data compiled from 3 replicates using 1 cell sort by flow cytometry).